Pfizer’s Meningitis B Vaccine Beats Novartis To Market, But ACIP Remains Key To Uptake
Executive Summary
The first-mover advantage for Trumenba remains unclear as CDC’s Advisory Committee on Immunization Practices holds crucial sway on vaccine use and commercial success; ACIP will vote on use of meningitis B vaccines in high-risk groups and during outbreaks in February 2015, but more widespread use recommendations may not be issued until late next year.